A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.
The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.

开始日期2024-01-11

申办/合作机构

AVEO Pharmaceuticals, Inc.

NCT04100330

/ Withdrawn临床2期

A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in subjects with relapsed or refractory acute myeloid leukemia.

开始日期2020-01-31

申办/合作机构

AVEO Pharmaceuticals, Inc.

[+1]

NCT03316599

/ Completed临床1期IIT

Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.

开始日期2018-01-17

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

100 项与 Ficlatuzumab 相关的临床结果

登录后查看更多信息

100 项与 Ficlatuzumab 相关的转化医学

登录后查看更多信息

100 项与 Ficlatuzumab 相关的专利（医药）

登录后查看更多信息

项与 Ficlatuzumab 相关的文献（医药）

2023-08-01·JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

Article

作者: Saba, Nabil F. ; Klein, Robert ; Wang, Steven ; Giri, Anshu ; Bhatia, Aarti ; Muzaffar, Jameel ; Burtness, Barbara ; Julian, Ricklie ; Bearelly, Shethal ; Bauman, Julie E. ; Caulin, Carlos ; Obara, Stefanie ; Bauman, Jessica R. ; Kaczmar, John ; Saboda, Kathylynn ; Baker, Audrey ; Roe, Denise ; Centuori, Sara ; Chung, Christine H. ; Steuer, Conor

PURPOSE:

Primary or acquired resistance to cetuximab, an antiepidermal growth factor receptor monoclonal antibody (mAb), minimizes its utility in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Aberrant hepatocyte growth factor/cMet pathway activation is an established resistance mechanism. Dual pathway targeting may overcome resistance.

PATIENTS AND METHODS:

This multicenter, randomized, noncomparative phase II study evaluated ficlatuzumab, an antihepatocyte growth factor mAb, with or without cetuximab in recurrent/metastatic HNSCC. The primary end point was median progression-free survival (PFS); an arm met significance criteria if the lower bound of the 90% CI excluded the historical control of 2 months. Key eligibility criteria were HNSCC with known human papillomavirus (HPV) status, cetuximab resistance (progression within 6 months of exposure in the definitive or recurrent/metastatic setting), and resistance to platinum and anti–PD-1 mAb. Secondary end points included objective response rate (ORR), toxicity, and the association of HPV status and cMet overexpression with efficacy. Continuous Bayesian futility monitoring was used.

RESULTS:

From 2018 to 2020, 60 patients were randomly assigned and 58 were treated. Twenty-seven versus 33 patients were allocated to monotherapy versus combination. Arms were balanced for major prognostic factors. The monotherapy arm closed early for futility. The combination arm met prespecified significance criteria with a median PFS of 3.7 months (lower bound 90% CI, 2.3 months; P = .04); the ORR was 6 of 32 (19%), including two complete and four partial responses. Exploratory analyses were limited to the combination arm: the median PFS was 2.3 versus 4.1 months ( P = .03) and the ORR was 0 of 16 (0%) versus 6 of 16 (38%; P = .02) in the HPV-positive versus HPV-negative subgroups, respectively. cMet overexpression was associated with reduced hazard of progression in HPV-negative but not HPV-positive disease ( P interaction = .02).

CONCLUSION:

The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.

2023-06-01·World neurosurgery

Computational Drug Discovery in Ankylosing Spondylitis–Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis

Article

作者: Wang, Liang ; Yuan, Jincan ; Wang, Haibin ; Lu, Xuhua ; Li, Qisheng ; Wang, Chenfeng ; Wu, Weiqing

BACKGROUND:

Ankylosing spondylitis (AS) and osteoporosis (OP) are both prevalent illnesses in spine surgery, with OP being a possible consequence of AS. However, the mechanism of AS-induced OP (AS-OP) remains unknown, limiting etiologic research and therapy of the illness. To mine targetable medicine for the prevention and treatment of AS-OP, this study analyzes public data sets using bioinformatics to identify genes and biological pathways relevant to AS-OP.

METHODS:

First, text mining was used to identify common genes associated with AS and OP, after which functional analysis was carried out. The STRING database and Cytoscape software were used to create protein-protein interaction networks. Hub genes and potential drugs were discovered using drug-gene interaction analysis and transcription factors-gene interaction analysis.

RESULTS:

The results of text mining showed 241 genes common to AS and OP, from which 115 key symbols were sorted out by functional analysis. As options for treating AS-OP, protein-protein interaction analysis yielded 20 genes, which may be targeted by 13 medications.

CONCLUSIONS:

Carlumab, bermekimab, rilonacept, rilotumumab, and ficlatuzumab were first identified as the potential drugs for the treatment of AS-OP, proving the value of text mining and pathway analysis in drug discovery.

2023-05-08·The oncologist

Phase Ib and Expansion Study of Gemcitabine,Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer

Article

作者: Aguirre, Andrew J ; Rustgi, Anil K ; Enzinger, Peter ; Germon, Victoria ; Bakir, Basil ; Raghavan, Srivatsan ; Goyal, Lipika ; Giannakis, Marios ; Weekes, Colin ; Giantonio, Bruce J ; Das, Koushik ; Needle, Michael ; Abrams, Thomas ; Stonely, Danielle ; Yurgelun, Matthew B ; Pitarresi, Jason R ; Chiarella, Anna M ; Perez, Kimberly ; Rubinson, Douglas ; Goessling, Wolfram ; Blaszkowsky, Lawrence ; Horick, Nora ; Meyerhardt, Jeffrey A ; Brais, Lauren ; Wolpin, Brian M ; Cleary, James M

Abstract:

Background:

In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.

Methods:

Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination.

Results:

Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose–limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy.

Conclusion:

In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.

项与 Ficlatuzumab 相关的新闻（医药）

2026-01-14

·PRNewswire

AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab

– Collaboration with Blood Cancer United® in its Beat AML® Master Clinical Trial – – AVEO's ficlatuzumab compound to be studied in combination with azacitidine and venetoclax in patients with AML in a Phase 1b/2 clinical trial – – First patient dosed into the Phase 1b/2 clinical trial – BOSTON, Jan. 14, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax in patients that are 60 years of age or older with untreated acute myeloid leukemia (AML) through a Master Clinical Trial Collaboration Agreement with Blood Cancer United®, formerly the Leukemia & Lymphoma Society. As part of this strategic collaboration with Blood Cancer United, a global nonprofit focused on blood cancer patient support, research, and advocacy, Blood Cancer United will be sponsoring the clinical trial as a sub-study in their Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer, which tests multiple therapies in multiple study arms simultaneously. The Phase 1b/2 clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination as a potential treatment for AML. Ficlatuzumab is AVEO's investigational humanized IgG1 monoclonal antibody that is designed to bind to the hepatocyte growth factor (HGF) ligand and prevent it from signaling via the c-Met receptor. Early phase clinical trials evaluating ficlatuzumab in combination with cytarabine in AML reported a favorable safety profile with promising clinical activity, supporting ficlatuzumab for further study in AML patients, particularly in those who are considered unfit for standard intensive first-line therapy. "This is a significant milestone for AVEO and Blood Cancer United, who are both dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO. "We welcome this partnership and are excited to collaborate on this important clinical trial as we continue to expand our efforts to address high unmet medical needs with our novel clinical stage portfolio of therapies." "The Beat AML Master Clinical Trial seeks to change the paradigm for how this deadly cancer is treated, using an innovative precision medicine protocol and implementing strategic partnerships," said Lore Gruenbaum, Ph.D, Chief Scientific Officer of Blood Cancer United. "Our collaboration with AVEO is a key next step for the trial and transforming patient care for adults with AML." About AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit . About Blood Cancer United® and the Beat AML® Master Clinical Trial Blood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives. For support and to learn more, visit . The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple sub-studies simultaneously and has already generated strong results, demonstrating positive survival rates and better quality of life. Over the past decade, Beat AML has grown into a powerful ecosystem of pharma companies, genetic testing experts, data specialists, regulatory agencies, and other industry partners working toward better and safer treatments for patients with AML. For more information, visit . About Ficlatuzumab Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling pathway. The U.S. Food and Drug Administration designated as a Fast Track development program the investigation of ficlatuzumab and ERBITUX® (cetuximab) for relapsed/recurrent HNSCC in September 2021, which is currently in a Phase 3 clinical study. Contacts Media: John F. Kouten JFK Communications, Inc. 908-227-4714 [email protected] SOURCE AVEO, an LG Chem company 21% more press release views with Request a Demo

临床3期快速通道

2026-01-14

·PRNewswire

Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment

WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat AML® Master Clinical Trial (Beat AML). In collaboration with AVEO Oncology, an LG Chem company, ("AVEO") the new sub-study is evaluating ficlatuzumab, a monoclonal antibody targeting hepatocyte growth factor (HGF), in combination with venetoclax and azacitidine in adults 60 years and older with newly diagnosed, untreated acute myeloid leukemia (AML). The new sub-study is open at the University of California San Francisco and The University of Kansas Medical Center. "The shift five years ago to venetoclax plus azacitidine as the standard of care for older adults with AML was practice-changing, but most patients still relapse, and long-term outcomes remain poor," said Blood Cancer United Chief Scientific Officer Lore Gruenbaum, Ph.D. "That's why we are actively investigating new triplet therapies like in this new sub-study. These combination therapies have the potential to improve survival and quality of life." New Triplet Sub-Study Builds on Beat AML Progress The latest sub-study is one of four that is currently open and is part of the Beat AML Master Clinical Trial, which tests multiple treatments for different subtypes under one master umbrella. Beat AML uses genomic testing to match patients with the most promising targeted treatment based on their unique genetic mutations. To date, more than 1,850 patients have received genomic testing within seven days of diagnosis, and more than 650 have enrolled in one of the Beat AML precision treatment sub-studies. Fourteen clinical sites are open in the United States, including recent additions at the University of Pittsburgh Medical Center and West Virgina University. Beat AML unites leading blood cancer experts, pharmaceutical partners, genomic testing firms, data specialists, clinical trial sites and regulators to break down silos and accelerate patient-focused discoveries. Two other sub-studies have recently achieved key milestones: Revumenib-Based Triplet Shows Strong Responses: An early phase Beat AML sub-study found that adding the menin inhibitor revumenib to ven/aza produced high rates of complete remission. The trial enrolled adults 60 and older with NPM1 mutations or KMT2A rearrangements. In the phase 1 trial, patients with KMT2A-rearranged AML who received the triplet combination had a median overall survival of 15.5 months. Historically, treatment with venetoclax and azacitidine alone results in a median overall survival of 2.5 months for these patients. Optimizing Shorter Treatment Cycles for Older AML Patients: Launched in June 2023, Opti-AML, a Beat AML sub-study, is studying whether a shorter duration of venetoclax treatment—14 days compared to the FDA-approved 28 days— combined with azacitidine can achieve a similar complete remission rate in newly diagnosed AML patients age 60 and older. The shorter duration is expected to speed blood count recovery, reduce infections, and lower the frequency of hospitalizations and blood transfusions. Patient enrollment in Opti-AML was completed in September 2025 with results expected in 2026. "Beat AML continues to exceed expectations and has evolved into what it is today, an extensive network of innovative therapeutic trials," says John Byrd, M.D., Beat AML Chief Medical Officer and UPMC Hillman Cancer Center Director. "Patients enrolled in a Beat AML treatment trial have achieved improved survival and better quality of life compared to those who received standard-of-care chemotherapy. As we approach 10 years, the master trial continues to advance the frontier of precision medicine in AML." About Blood Cancer United ® and the Beat AML ® Master Clinical Trial Blood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives. For support and to learn more, visit . The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple sub-studies simultaneously and has already generated strong results, showing superior survival rates and better quality of life. Over the past decade, Beat AML has grown into a powerful ecosystem of pharma companies, genetic testing experts, data specialists, regulatory agencies, and other industry partners working toward better and safer treatments for patients with AML. For more information, visit Media Contact: Ryan McDonald Blood Cancer United [email protected] SOURCE Blood Cancer United® formerly The Leukemia & Lymphoma Society 21% more press release views with Request a Demo

临床结果临床1期临床研究临床2期ASCO会议

2025-11-05

·LG化学

LG化学正式开发肾细胞癌创新疗法

11月5日，LG化学宣布旗下抗癌新药研发公司AVEO与美国生物科技公司HiberCell达成合作，签署了有关Ⅰ期临床试验新药物质HC-5404的全球独家研发及行使选择权合作协议。据此，LG化学将引进肾细胞癌治疗剂“FOTIVDA(成分名称：Tivozanib)”和有望发挥协同作用的新药物质，正式推出新型治疗方案。通过此次协议，LG化学将直接进行Ⅰb期临床试验，并在Ⅱ期临床阶段决定是否签订确保相关物质全球独家许可的选择权协议。LG化学将向HiberCell支付非公开定金，今后在行使选择权时，将分阶段支付研发及商业化费用、销售特许使用权费用。 HiberCell是一家专注于研发预防癌症复发及转移新型疗法的生物科技公司，其核心新药物质HC-5404是全球首款进入临床阶段的蛋白激酶R样内质网激酶(protein kinase R (PKR)-like endoplasmic reticulum kinase, PERK)抑制剂。血管生成抑制剂是通过阻断向癌细胞供应营养成分和氧气的路径，从而抑制肿瘤细胞的生成。临床前研究结果表明，在肾细胞癌、胃癌等多种实体瘤动物模型中，当HC-5404新药物质与血管生成抑制剂联合使用时，具有增强和延长抗肿瘤功效的潜力。通过此次合作，LG化学将验证血管生成抑制剂“FOTIVDA”和HC-5404新药物质联合疗法的突破性潜力，并以此为契机，进一步扩大肾细胞癌患者的治疗机会。 LG化学生命科学事业本部长孙智雄表示 “LG化学将以抗癌新药研发，持续引领生命科学领域的业务增长，致力于为全球癌症患者提供多元化的创新治疗方案。” 面对持续增长的全球抗癌药物市场需求，LG化学正运营着多个处于临床阶段的新药课题。头颈癌新药“Ficlatuzumab”正进行Ⅲ期临床试验，持续加速商业化进程；针对抗癌治疗而引起体重和肌肉减少的癌症恶病质治疗剂“Rilogrotug”、免疫检查点抑制剂“LB-LR1109”项目均正在进行Ⅰ期临床试验。探索更多

临床2期临床1期临床3期

100 项与 Ficlatuzumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10123	Ficlatuzumab	-	DB11680

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性头颈部鳞状细胞癌	临床3期	美国	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	澳大利亚	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	比利时	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	保加利亚	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	加拿大	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	捷克	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	法国	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	德国	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	匈牙利	AVEO Pharmaceuticals, Inc.	2024-01-11
复发性头颈部鳞状细胞癌	临床3期	意大利	AVEO Pharmaceuticals, Inc.	2024-01-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03013998 (Beat AML Master Trial, ASH2025)	临床1/2期	急性髓性白血病	66	Ficlatuzumab+Venetoclax+Azacitidine	鏇獵糧願憲願範壓憲膚(觸積壓獵鏇壓壓廠艱廠) = 淵鑰繭範餘鹹範範獵壓鑰糧鏇淵襯淵選壓淵廠 (鬱鑰壓淵獵顧鹹觸簾膚 )	积极	2025-12-06
ASTRO2024	N/A	复发性头颈部鳞状细胞癌	-	Ficlatuzumab 10mg/kg + Cetuximab 500mg/m2	餘鏇衊膚選簾艱積願齋(廠糧鏇鹹獵夢積積壓製) = 齋鹽壓壓製窪網糧構範積製選願餘積鹹壓繭遞 (鏇餘醖鑰窪遞襯齋蓋艱 ) 更多	-	2024-10-01
NCT02318368 (FOCAL, CTgov)	临床2期	转移性非小细胞肺癌 \| EGFR突变的非小细胞肺癌	10	Erlotinib+Ficlatuzumab (Ficlatuzumab Plus Erlotinib)	衊範選網襯艱繭衊壓鬱 = 繭蓋獵鑰壓襯選糧範獵衊顧製夢夢鑰製積構獵 (淵築構願構淵壓鬱蓋鏇, 願糧觸衊鏇構網獵蓋廠 ~ 築膚壓廠夢艱簾簾選夢) 更多	-	2020-10-22
NCT02318368 (FOCAL, CTgov)	临床2期	转移性非小细胞肺癌 \| EGFR突变的非小细胞肺癌	10	placebo+Erlotinib (Placebo Plus Erlotinib)	衊範選網襯艱繭衊壓鬱 = 遞鑰選鏇醖範醖蓋顧廠衊顧製夢夢鑰製積構獵 (淵築構願構淵壓鬱蓋鏇, 獵廠衊襯製製繭艱鏇獵 ~ 淵鏇淵構範構餘鏇構衊) 更多	-	2020-10-22
NCT02277197 (Pubmed \| Cancers (Basel)) 人工标引	临床1期	头颈部鳞状细胞癌	13	Ficlatuzumab+Cetuximab	艱艱積網壓願選淵鑰觸(簾顧築醖窪鹽積願鬱餘) = cetuximab 500 mg/m2 and ficlatuzumab 20 mg/kg every 2 weeks 觸網構願糧鏇壓鹹鑰衊 (蓋鏇觸築醖窪網選艱齋 )	积极	2020-06-11
NCT03316599 (ASCO_GI 12020 \| ASCO_GI 22020) 人工标引	临床1期	胰腺癌一线	24	gemcitabine+nab-paclitaxel+ficlatuzumab	艱憲廠蓋廠窪蓋網鏇餘(淵積簾蓋鏇鏇憲獵衊鹽) = 構齋夢顧鑰獵糧餘願夢膚廠夢簾選製獵繭鏇蓋 (艱鑰構蓋廠構選鹹製觸 ) 更多	积极	2020-01-24
NCT02109627 (AACR2018)	临床1期	急性髓性白血病 serum hepatocyte growth factor (HGF) level	-	Ficlatuzumab	艱膚齋廠選醖齋艱簾醖(衊鹽鑰積網餘夢鏇願齋) = 顧襯選觸衊鹽襯艱觸鑰衊蓋構鑰顧遞淵餘鏇範 (鬱顧窪鹽願繭襯蓋襯艱 )	-	2018-07-01
NCT01039948 (Pubmed \| Clin Pharmacol Drug Dev) 人工标引	临床1期	非小细胞肺癌	15	Gefitinib+Ficlatuzumab (10mg/kg)	-	积极	2018-06-01
NCT01039948 (Pubmed \| Clin Pharmacol Drug Dev) 人工标引	临床1期	非小细胞肺癌	15	Gefitinib+Ficlatuzumab (20mg/kg)	構蓋構淵齋膚鹹鏇膚遞(醖製夢範壓鹽繭廠積醖) = 觸夢繭製願範鏇積醖壓繭構襯遞構鏇築廠顧願 (鑰餘製觸構鑰憲鬱範蓋 ) 更多	积极	2018-06-01
NCT02277197 (ASCO2017)	临床1期	复发性头颈部鳞状细胞癌	12	Cetuximab 500 mg/m2	選簾襯鏇憲簾窪繭觸願(選餘齋餘夢鬱鬱餘顧艱) = 鹹壓糧鬱鑰醖繭製衊醖齋蓋觸選齋遞遞醖網醖 (衊簾醖襯醖糧觸築廠夢, 2.7 ~ Not reached) 更多	-	2017-05-30
NCT02109627 (CyFi, ASCO2017)	临床1期	急性髓性白血病	9	Ficlatuzumab + High-dose cytarabine	築艱鏇鑰壓糧顧鹽網鹽(顧築繭窪顧簾鏇齋膚選) = There was 1 death (11%) from sepsis and multi-organ failure on day 23, following ANC recovery. 淵顧衊製繭鹽蓋齋衊壓 (膚鑰鹹簾襯憲膚膚膚齋 ) 更多	积极	2017-05-30
NCT01039948 (P06162, Pubmed \| J Thorac Oncol) 人工标引	临床2期	肺腺癌	188	Gefitinib+Ficlatuzumab	繭網構願憲壓獵築淵顧(襯遞糧夢簾憲蓋壓觸願) = did not provide significant improvement 醖選廠夢繭繭醖餘鹽簾 (襯獵鏇鹹顧餘糧淵構鹽 ) 更多	不佳	2016-10-01
NCT01039948 (P06162, Pubmed \| J Thorac Oncol) 人工标引	临床2期	肺腺癌	188	Gefitinib		不佳	2016-10-01